Intravenous steroids for allergic reaction

The overall remission (OR) rate (Complete Remission [CR] + CR in the absence of total platelet recovery [CRp]) was evaluated. CR was defined as no evidence of circulating blasts or extramedullary disease, an M1 bone marrow ( ≤ 5% blasts), and recovery of peripheral counts [platelets ≥ 100 x 10 9/ L and absolute neutrophil count (ANC) ≥ x 10 9/ L]. CRp was defined as meeting all criteria for CR except for recovery of platelet counts to ≥ 100 x 10 9/ L. Partial Response (PR) was also determined, defined as complete disappearance of circulating blasts, an M2 bone marrow ( ≥ 5% and ≤ 25% blasts), and appearance of normal progenitor cells or an M1 marrow that did not qualify for CR or CRp. Duration of remission was also evaluated. Transplantation rate was not a study endpoint.

Perhaps a more popular theory is that the immunosuppressive effects of immunoglobulin therapy are mediated through IgG's Fc glycosylation. By binding to receptors on antigen presenting cells, IVIG can increase the expression of the inhibitory Fc receptor , FcgRIIB and shorten the half-life of auto-reactive antibodies. [20] [21] [22] The ability of immunoglobulin therapy to suppress pathogenic immune responses by this mechanism is dependent on the presence of a sialylated glycan at position CH2- of IgG. [20] Specifically, de-sialylated preparations of immunoglobulin lose their therapeutic activity and the anti-inflammatory effects of IVIG can be recapitulated by administration of recombinant sialylated IgG1 Fc. [20]

Intravenous steroids for allergic reaction

intravenous steroids for allergic reaction

Media:

intravenous steroids for allergic reactionintravenous steroids for allergic reactionintravenous steroids for allergic reactionintravenous steroids for allergic reactionintravenous steroids for allergic reaction